Title:  Ibritumomab for the Treatment of B-Cell Lymphoma in Adults: Clinical Effectiveness and Guidelines For Use

Date:  17 June 2008

Research question:

1. What is the clinical effectiveness and safety of ibritumomab for the treatment of B-cell lymphoma in adults?

2. What are the guidelines for use of ibritumomab for the treatment of B-cell lymphoma in adults?

Methods:

A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 2, 2008) University of York Centre for Reviews and Dissemination (CRD) databases, ECRI, EuroScan, international HTA agencies, and a focused Internet search. Results include articles published between 2003 and June 2008, and are limited to English language publications only. No filters were applied to limit the retrieval by study type. Internet links are provided, where available.

Results:

HTIS reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews and meta-analyses are presented first. These are followed by randomized controlled trials, observational studies and evidence-based guidelines.

One systematic review, 15 observational studies and three evidence-based guidelines were identified from the literature search results. No relevant health technology assessments or randomized controlled trials examining the clinical effectiveness or safety of ibritumomab for the treatment of B-cell lymphoma in adults were identified.
Health technology assessments
No literature identified

Systematic reviews and meta-analyses

Randomized controlled trials
No literature identified

Observational studies


**Guidelines and recommendations**


Appendix – Further information:

Review articles


Additional references


